Today: 9 June 2026
Browse Category

NYSE:NAT 7 January 2026 - 12 January 2026

DHT Holdings stock faces Monday test as oil rally and VLCC rates collide

DHT Holdings stock faces Monday test as oil rally and VLCC rates collide

DHT Holdings shares slipped 0.1% to $13.42 Friday, with trading volume at 2.3 million. The Baltic Exchange’s VLCC benchmark for Middle East Gulf-to-China rose 24 points to WS74.17, pushing daily charter rates to about $55,540. Oil prices climbed roughly 2% last week on supply concerns tied to unrest in Iran and Venezuela. DHT’s new VLCC, the Antelope, began spot market operations this month.
12 January 2026
··
DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

DHT Holdings shares jumped 6.6% to $12.81 in New York as U.S. officials moved to allow Venezuelan crude imports and ease some sanctions. Oil prices slipped, with Brent down 0.7% at $60.31 a barrel. The U.S. Coast Guard seized a Russian-flagged tanker linked to Venezuelan oil after a two-week pursuit. Investors tracked signs of cargo rerouting and upcoming U.S. oil inventory data.
7 January 2026
·····

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
Go toTop